Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Terns Pharmaceuticals, Inc. (TERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.77-0.04 (-0.69%)
At close: 04:00PM EST
5.91 +0.14 (+2.43%)
After hours: 04:09PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.81
Open5.72
Bid5.74 x 800
Ask7.50 x 800
Day's Range5.59 - 6.13
52 Week Range5.43 - 28.36
Volume61,185
Avg. Volume72,160
Market Cap145.792M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.13
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TERN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Terns Pharmaceuticals, Inc.
    EXTR: Lowering target price to $14.00EXTREME NETWORKS INC has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

    FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced the appointment of Jeffrey R. Jasper, Ph.D., as senior vice president, head of research. Dr. Jasper joins Terns with more than 28 years of experience in

  • GlobeNewswire

    Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

    FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), today announced that the Company’s management team will present at the following investor conferences in January: 40th Annual J.P. Morgan Health Care Conference Date: J

  • GlobeNewswire

    Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

    -Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022 -Positive top-line data from TERN-501 (THR-β) demonstrated clinical proof of concept, enabling the planned initiation of NASH trial in 1H 2022 -Multiple abstracts detailing positive clinical data for TERN-101 and TERN-501 presented at AASLD 2021 -Cash and equivalents of $177 million provides runway into 2024 FOSTER CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Co

Advertisement
Advertisement